We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Merck KGaA (PK) | USOTC:MKKGY | OTCMarkets | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.21 | 0.65% | 32.28 | 32.26 | 32.68 | 32.85 | 31.90 | 32.406 | 46,985 | 20:21:50 |
By Cecilia Butini
Merck KGaA said Wednesday that earnings and revenue rose in the first quarter, driven by all its business division but especially life science.
After-tax profit at the German pharmaceuticals-and-chemicals company came in at 748 million euros ($908.9 million) for the quarter, up from EUR458 million in the same quarter a year prior.
Earnings before interest, taxes, depreciation and amortization before one-time items, or Ebitda pre, stood at EUR1.51 billion, compared with EUR1.18 billion in the first quarter of 2020, as the company had communicated in a preliminary statement on May 4.
Net sales came in at EUR4.63 billion, up from EUR4.37 billion, which had also already been communicated in a preliminary statement.
For the full year, sales are expected to come in between EUR18.5 billion and EUR19.5 billion, a guidance increase that had been previously communicated in a preliminary statement. Ebitda pre is seen coming in between EUR5.4 billion and EUR5.8 billion, the company said. That compares with a previous guidance of strong organic growth.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
May 12, 2021 01:41 ET (05:41 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Merck KGaA (PK) Chart |
1 Month Merck KGaA (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions